Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nevada PSE bill

This article was originally published in The Tan Sheet

Executive Summary

State lawmakers Feb. 22 introduced A.B. 150 to limit the diversion of pseudoephedrine-containing OTC medicines to methamphetamine production by requiring prescriptions for the products, along with those made with ephedrine and phenylpropanolamine. The Consumer Healthcare Products Association strongly opposes the bill and will express its concerns in Nevada the week of Feb. 26. The bill is modeled after a 2005 Oregon law (1"The Tan Sheet" Aug. 22, 2005, p. 5). The Bush administration has said it will monitor the effectiveness of behind-the counter provisions of the federal Combat Meth Act as well as stricter state strategies (2"The Tan Sheet" June 12, 2006, p. 6)...
Advertisement

Related Content

Nevada Rx PSE bill dies
Meth Strategy Includes Tracking Success Of National Versus State Policies
Oregon Pseudoephedrine Law Requires Prescription Status By July 2006
Oregon Pseudoephedrine Law Requires Prescription Status By July 2006

Topics

Advertisement
UsernamePublicRestriction

Register

PS100255

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel